Yet with up to 55% of indicators presented to payors being irrelevant to their decision-making needs, problems with evidence submitted at the payor level can create unnecessary obstacles and delays to medicine adoption or even halt it in its tracks.

Our distinctive multiple-stakeholder approach ensures that the generation of real-world evidence matches payors’ needs, ensuring that your new medicine or therapy has the best chance of reaching the highest number of patients in the fastest possible time.